Serina Therapeutics (SER) Total Non-Current Liabilities (2022 - 2025)
Historic Total Non-Current Liabilities for Serina Therapeutics (SER) over the last 4 years, with Q2 2025 value amounting to $3.7 million.
- Serina Therapeutics' Total Non-Current Liabilities fell 7263.3% to $3.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was $3.7 million, marking a year-over-year decrease of 7263.3%. This contributed to the annual value of $2.6 million for FY2024, which is 4578.02% down from last year.
- As of Q2 2025, Serina Therapeutics' Total Non-Current Liabilities stood at $3.7 million, which was down 7263.3% from $2.6 million recorded in Q1 2025.
- Serina Therapeutics' Total Non-Current Liabilities' 5-year high stood at $32.2 million during Q1 2023, with a 5-year trough of $2.6 million in Q1 2025.
- For the 4-year period, Serina Therapeutics' Total Non-Current Liabilities averaged around $12.6 million, with its median value being $13.7 million (2024).
- The largest annual percentage gain for Serina Therapeutics' Total Non-Current Liabilities in the last 5 years was 15361.65% (2023), contrasted with its biggest fall of 7615.82% (2023).
- Over the past 4 years, Serina Therapeutics' Total Non-Current Liabilities (Quarter) stood at $20.4 million in 2022, then tumbled by 76.16% to $4.9 million in 2023, then tumbled by 45.78% to $2.6 million in 2024, then soared by 42.22% to $3.7 million in 2025.
- Its Total Non-Current Liabilities was $3.7 million in Q2 2025, compared to $2.6 million in Q1 2025 and $2.6 million in Q4 2024.